Clinical Trials | June 01, 2026
Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial
This marks one of the most closely watched oncology readouts at this year’s medical congress
This marks one of the most closely watched oncology readouts at this year’s medical congress
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Subscribe To Our Newsletter & Stay Updated
